Dipika Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.51 M
as on 16-11-2024
- Company Age 21 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 13.11 Cr
as on 16-11-2024
- Satisfied Charges ₹ 2.10 Cr
as on 16-11-2024
- Revenue 261.31%
(FY 2023)
- Profit 224.96%
(FY 2023)
- Ebitda 647.28%
(FY 2023)
- Net Worth 14.04%
(FY 2023)
- Total Assets 5.87%
(FY 2023)
About Dipika Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.51 M.
The company currently has active open charges totaling ₹13.11 Cr. The company has closed loans amounting to ₹2.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dipika Mandal, Chandra Mandal, Kiran Mandal, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397WB2003PTC096389
- Company No.
096389
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dipika Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dipika Mandal  | Director | 13-Jun-2003 | Current |
| Chandra Mandal | Director | 13-Jun-2003 | Current |
| Kiran Mandal | Director | 15-Jan-2018 | Current |
| Raj Mandal | Director | 15-Jan-2018 | Current |
Financial Performance of Dipika Pharmaceuticals.
Dipika Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 261.31% increase. The company also saw a substantial improvement in profitability, with a 224.96% increase in profit. The company's net worth Soared by an impressive increase of 14.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dipika Pharmaceuticals?
In 2023, Dipika Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 25 May 2022 | ₹1.64 Cr | Open |
Hdfc Bank Limited Creation Date: 31 Jan 2022 | ₹0.70 M | Open |
Hdfc Bank Limited Creation Date: 12 Nov 2021 | ₹1.35 Cr | Open |
How Many Employees Work at Dipika Pharmaceuticals?
Dipika Pharmaceuticals has a workforce of 33 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dipika Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dipika Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
